YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:…
Quick Read KYTX dropped 12% after JPMorgan trimmed its price target to $29, despite beating Q1 estimates and initiating a rolling BLA for miv-cel targeting a 2027 launch. BEAM slid 8% from a 52-week high and ALLO dropped 5%, while myasthen…
Jacob Funds, a mutual fund company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The recent quarter began against the backdrop of the war in the Middle East and concerns about AI disruption…
Pharmaceutical companies can offer investors huge returns if treatments under development become blockbuster drugs. Choosing between a speculative clinical-stage play and a dominant cash-flow engine requires careful thought, however. Decid…
(RTTNews) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multiple therapeutic areas, including Wilson's Disease, Ovaria…
(RTTNews) - Kyverna Therapeutics, Inc. (KYTX), a late-stage clinical biopharmaceutical company, announced positive primary analysis results from its registrational Phase 2 trial, KYSA-8, of miv-cel or KYV-101 in stiff person syndrome or SP…
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS Data underscore potential for miv-cel to…
[Myasthenia gravis is shown using the text] Andrii Dodonov Shares of Kyverna Therapeutics (KYTX [https://seekingalpha.com/symbol/KYTX]) rose on Monday after the company announced long-term follow-up data from a pivotal trial for its lead a…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary l…
TOI Management, LLC CERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Minh Merchant has joined…
Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated KYSA-6 Phase 2 data in generalized myasthenia gravis (gMG) EMERYVILLE, Calif., March 0…
Quick Read EyePoint (EYPT), Janux (JANX), Kyverna (KYTX), and Viking (VKTX) have analyst targets implying 179% to 384% upside. Janux and Kyverna hold the highest upside projections at 384% and 308% respectively, with unanimous Buy ratings.…
Kyverna Therapeutics’ KYTX lead CAR T-cell therapy candidate, mivocabtagene autoleucel (“miv-cel”, formerly KYV-101), is being developed in a pivotal phase II study for stiff person syndrome (SPS), a rare, debilitating and progressive auto…
(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were announced during the week, with GSK, Halozy…
Shares of Kyverna Therapeutics KYTX surged 23.2% on Monday after the company reported positive top-line data from a registrational mid-stage study of its investigational candidate, mivocabtagene autoleucel (miv-cel, formerly KYV-101), for…
After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements with the Trump administration. A rebound i…
[Stock Market] sweetym/iStock via Getty Images U.S. stock futures retreated Tuesday as investors adopted a cautious stance ahead of November’s employment data, a key indicator for the labor market’s health. Here are some of Tuesday's bigge…
The S&P 500(SNPINDEX:^GSPC) slipped 0.16% to 6,816.34, the Nasdaq Composite(NASDAQINDEX:^IXIC) fell 0.59% to 23,057.41 on continued AI and tech weakness, and the Dow Jones Industrial Average (DJINDEX: ^DJI) eased 0.09% to 48,416.57 in caut…
EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host…
Biotech investors hunting for explosive growth may want to look closely at two emerging innovators making significant progress in high-impact therapeutic areas. Kyverna Therapeutics (KYTX) is advancing its breakthrough CAR T-cell programs…
* Kyverna Therapeutics press release [https://seekingalpha.com/pr/20305094-kyverna-therapeutics-provides-business-update-and-reports-third-quarter-2025-financial] (KYTX [https://seekingalpha.com/symbol/KYTX]): Q3 GAAP EPS of -$0.85 misses…
Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive interim Phase 2 data in generalized myasth…
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company’s registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically meaningful responses in MG-ADL and QMG…
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a well-tolerated profile, consisten…
Kyverna Therapeutics Inc. (NASDAQ:KYTX) is one of the best young stocks with huge upside potential. On October 8, Wells Fargo analyst Derek Archila raised the firm’s price target on Kyverna Therapeutics to $27 from $24, while maintaining a…
NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf o…
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101 continues to demonstrate a tolerable saf…
Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate by year-end 2025 EMERYVILLE, Calif., Se…
KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase 3 trial design for myasthenia gravis suppor…
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Wa…
Investing.com - William Blair initiated coverage on Kyverna Therapeutics Inc (NASDAQ:KYTX), currently valued at $152 million, with an Outperform rating and set a $27 fair-value estimate. The stock currently trades significantly below analy…
* Kyverna Therapeutics press release [https://seekingalpha.com/pr/20198562-kyverna-therapeutics-provides-business-update-and-reports-second-quarter-2025-financial] (NASDAQ:KYTX [https://seekingalpha.com/symbol/KYTX]): Q2 GAAP EPS of -$0.97…
Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) and BLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to ini…
SAN RAFAEL, Calif., Aug. 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Ian T. Clark to the company's Board of Directors, effective today, August 1, 2025.BioMarin Pharmaceutical…
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 30, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) announced that Marc Grasso, M.D. has been appointed as the company’s new Chief Financial…
Over the past year, the United States market has seen a 13% rise, although it remained flat over the last week, with earnings forecasted to grow by 15% annually. In this context of steady growth and future potential, identifying stocks wit…